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Abstract
Background—Intestinal ischemia can quickly escalate to bowel necrosis and perforation. 
Transplantation of stem cells presents a novel treatment modality for this problem. We 
hypothesized that: (1) Human adipose derived stromal cells (hASCs) would increase survival and 
mesenteric perfusion to a greater degree compared to differentiated cellular controls following 
ischemic intestinal injury, (2) improved outcomes with hASC therapy would be associated with 
preservation of intestinal histological and tight junction architecture, and lower levels of systemic 
inflammation following intestinal injury.
Methods—hASCs and keratinocytes (differentiated cellular control) were cultured on 
polystyrene flasks at 37C in 5% CO2 in air. Adult male C57Bl6J mice were anesthetized and a 
midline laparotomy performed. The intestines were eviscerated, the small bowel mesenteric root 
identified, and intestinal ischemia was established by temporarily occluding the superior 
mesenteric artery for 60 minutes with a non-crushing vascular clamp. Following ischemia, the 
clamp was removed and the intestines were returned to the abdominal cavity. Prior to abdominal 
closure, two million hASCs or keratinocytes in 250 uL of PBS (carrier for cells and control 
solution) were infused into the peritoneum. Animals were allowed to recover for 12 or 24 hours 
(perfusion, histology, cytokine, and immunofluoresence studies), or 7 days (survival studies). 
Intestinal perfusion was assessed by laser Doppler imaging. Intestinal tissue segments were 
stained with H&E, as well as antibodies for the tight junction protein claudin-1. Separate aliquots 
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of intestine, liver and lung tissue were homogenized and assessed for inflammatory cytokines via 
multiplex beaded assay.
Results—Animals administered hASCs following intestinal ischemia and reperfusion injury 
(I/R) had significantly greater 7 day survival and better post-ischemic recovery of mesenteric 
perfusion compared to vehicle or keratinocyte therapy. hASCs also abated intestinal mucosal 
destruction, facilitated preservation of intestinal tight junctions, and decreased the systemic 
inflammatory response to injury.
Conclusion—Human adipose derived stromal cells improved survival and mesenteric perfusion 
and attenuated the mucosal damage associated with intestinal ischemia and reperfusion injury. 
hASCs should be considered as a plausible cell source for novel cellular treatment plans following 
intestinal ischemia.
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INTRODUCTION
Intestinal ischemia and necrosis affect multiple patient populations of varying ages and 
comorbidities. Acute mesenteric ischemia (AMI) is prevalent in the elderly population and 
those who undergo cardiac bypass surgery [1]. AMI affects nearly 5000 patients annually, 
with many requiring open or endovascular surgical intervention to lyse the clot and salvage 
the ischemic intestine. The mortality rate for AMI can be as high as 40% for those who 
progress to surgery [2]. Necrotizing enterocolitis and volvulus are two forms of intestinal 
ischemia that can affect the neonatal population [3]. Necrotizing enterocolitis, which 
ultimately manifests as intestinal ischemia and necrosis, affects the very low birth weight 
premature population. The mortality for the most severe cases of necrotizing enterocolitis 
can be quite high [4]. Midgut volvulus associated with malrotation occurs much less 
frequently, but carries a high mortality when a majority of the bowel is involved [5]. In any 
case, if injury is unrecognized or left untreated, patients can quickly decompensate and 
progress to shock, multi-system organ failure, and death. If patients survive these ischemic 
episodes, they are often faced with prolonged hospitalization and long term parenteral 
nutrition needs [6].
Noteworthy advancements in the medical treatment of intestinal ischemia within the last 
decade have been sparse, and therefore, stromal cell therapy offers a novel therapeutic option 
for the treatment of this disease [6]. Bone marrow-derived mesenchymal stromal cells 
(BMSCs), in particular, have shown the capacity to promote survival and attenuate intestinal 
ischemic injury [3]. These advantages are achieved, in part, through enhanced restitution and 
improved integrity of the intestinal mucosa, reduced translocation of bacteria from the lumen 
into the circulation, and a decreased inflammatory response [7, 8].
In spite of their promising potential, BMSC use may be limited secondary to lower 
proliferative capacity and painful isolation procedures [9] [10]. Adipose-derived 
mesenchymal stromal cells (ASCs), however, show greater proliferative potential than 
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BMSCs and other mesenchymal stromal cell lines, and their ease of accessibility and 
limitless supply via liposuction of subcutaneous adipose tissue make them an ideal candidate 
for widespread therapeutic use [11-13]. ASCs have also been suggested as an alternative 
stem cell source for the treatment of intestinal ischemia in a rat model of intestinal I/R [14]. 
In this study, rat derived ASCs decreased inflammation and preserved intestinal histological 
architecture, but the cellular effects on survival and mesenteric perfusion were not defined.
Adipose stromal cell transplants have also been shown to improve recovery of damaged 
tissue in several other models including critical limb ischemia [15], acute kidney injury [16], 
cardiac ischemia [17], and stroke [18], but human ASCs (hASCs) have not yet been tested 
in preclinical models of intestinal ischemia. Therefore, the aim of the current study was to 
determine the efficacy of human ASC therapy in a murine model of intestinal ischemia and 
reperfusion injury (I/R). We hypothesized that: (1) hASCs would increase seven day survival 
and mesenteric perfusion compared to differentiated cellular controls following intestinal 
I/R; (2) improved outcomes with hASC therapy would be associated with preserved 
intestinal histology and tight junctional architecture following injury, and 3) hASAC therapy 
following intestinal I/R would limit intestinal and systemic inflammation.
MATERIALS AND METHODS
Cell Culture
Human ASCs were harvested from human subjects via liposuction and purified as 
previously described [19]. Briefly, human subcutaneous adipose tissue samples obtained 
from liposuction procedures were digested in collagenase type I (Worthington Biochemical, 
Lakewood, NJ) under agitation for 2 hours at 37°C. Samples were then centrifuged at 300g 
for 8 minutes to separate the stromal cell fraction (pellet) from adipocytes. The pellet was 
resuspended in DMEM/F12 containing 10% FBS (Hyclone, Logan, Utah) filtered through 
250-μm Nitex filters (Sefar America Inc, Kansas City, Mo) and centrifuged at 300g for an 
additional 8 minutes. The cell pellet was treated with red cell lysis buffer and was 
resuspended in EBM-2 with 5% FBS or EGM2-MV (Lonza, Allendale, NJ). Adipose 
stromal cells were CD34+, CD31−, and CD144− by flow cytometry, but also expressed 
several mesenchymal cell lineage markers including CD10, CD13, and CD90 [19]. Cells 
were cultured on polystyrene flasks in Endothelial Growth Medium 2 MV with 5% FBS at 
37C in 5% CO2 in air. Cells were used between passages 4-7.
Human nTERT keratinocytes were graciously donated by Dr. Jeffery Travers at the Indiana 
University School of Medicine. Cells were originally purchased through ATCC (Manassas, 
VA) and were cultured in Epilife medium with keratinocyte growth factor (Life 
Technologies, Grand Island, NY). Cells were used between passages 24 and 35.
Once ready for experimentation, cell disassociation was achieved using TrypLE Express 
(Life Technologies). Cells were then pelleted at 400g for 5 mins and resuspended in fresh 
media. Cells were then counted with the aid of an automated fluorescent cell counter (Luna-
FL Automated Cell Counter, Logos Biosystems, Annandale, VA). Two million hASCs or 
keratinocytes were then resuspended in 250ul of PBS vehicle for infusion as determined by a 
previous stromal cell dose response curve [3].
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Murine Intestinal Ischemia-Reperfusion Model
The experimental protocol and animal use were approved by the Indiana University 
Institutional Animal Care and Use Committee. Adult male C57Bl6J mice (8-12 weeks, 
20-30g; Jackson Labs, Bar Harbor, ME) were allowed 48 hours for acclimation to the new 
environment prior to intervention. They had access to normal chow and were kept in 12 hour 
light-dark cycle housing. The animals were anesthetized at 3% isoflurane and maintained at 
1.5% isoflurane for the duration of the procedure. Animals were placed on a heating pad to 
maintain body temperature during the procedure. The abdomen was prepped with hair 
removal lotion, followed by 70% ethanol and betadine. One milliliter of 0.9% normal saline 
was injected subcutaneously, and a midline laparotomy was performed.
The intestines were eviscerated, and the root of the superior mesenteric artery (SMA) was 
located. Temporary occlusion of the mesenteric root was established for 60 minutes using a 
non-crushing microvascular clamp. During ischemia, the abdomen was temporarily closed 
using silk suture to prevent evaporative heat and water loss. Following ischemia, the 
abdomen was reopened, the clamp was removed, and the intestines were allowed to recover. 
The abdominal fascia and skin were then closed in two layers using silk sutures. Prior to 
complete closure of the facial defect, 2 million hASCs, 2 million keratinocytes, or 250 μL of 
phosphate-buffered saline (PBS) vehicle were administered directly into the peritoneal 
cavity. Triple antibiotic ointment was applied to the abdominal incision site following 
complete closure, and analgesia (1 mg/kg buprenorphine and 5 mg/kg caprofen) was 
injected subcutaneously. Animals were recovered from anesthesia on the heating pad, placed 
back in their cage, and returned to animal housing.
Survival Analysis
Animals assigned to the survival protocol (n=10 I/R + hASC, 10 I/R + keratinocytes, 10 I/R 
+ PBS vehicle) were monitored twice daily over 7 days after the surgery for death, pain, and 
incisional complications. End points of analysis included animal death or when Laboratory 
Animal Resource Center veterinarians felt that animals were suffering and needed to be 
euthanized. Survival curves were then created based on these end points.
Laser Doppler Imaging Analysis
Laser Doppler Imaging (LDI)(Moor Instruments, Wilmington, DE) was used to assess blood 
perfusion of the intestines. At each designated time point, (baseline, initiation of ischemia, 
initiation of reperfusion, 12 or 24 hours of reperfusion) three LDI Readings were taken for 
each animal and an average perfusion value was calculated based on the flux mean of the 
three images. The flux mean value was a unit-less numerical value, with larger numbers 
representing greater perfusion, and smaller numbers representing lower perfusion or 
ischemia. The readings for each animal were expressed as a percentage of their baseline 
perfusion, with baseline representing 100% perfusion.
Animals assigned to the 12 hour (N=6/group) and 24 hour (N=7/group) reperfusion group 
were reanesthetized at 12 or 24 hours respectively. The incision site was reopened and the 
intestines were eviscerated. Laser Doppler imaging was then used to assess final perfusion 
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parameters. Animals were then euthanized by isoflurane overdose and cervical dislocation. 
Animals that died prior to analysis were arbitrarily assigned a perfusion value of zero.
Histology
After 12 and 24 hours of reperfusion, animals were euthanized and intestinal segments 
harvested. Segments were placed into 4% paraformaldehyde and subsequently dehydrated in 
70% ethanol. Segments were then paraffin embedded and cut using a microtome. Tissue 
segments were placed on slides and were stained with hematoxalin and eosin. Histologic 
scoring of the depth of tissue injury was performed in blinded fashion by two of the authors 
as we have previously described [20]: 0, no damage; 1, subepithelial space at the villous tip; 
2, loss of mucosal lining of the villous tip; 3, loss of less than half of the villous structure; 4, 
loss of more than half of the villous structure; 5, transmural necrosis (N= 6-7 intestinal 
segments/group).
Immunofluorescence
Paraffin embedded small intestinal blocks (N=6-7/group) were cut in 10μm segments. Slides 
were deparaffinized with xylene and rehydrated in graded alcohols. Heat-induced epitope 
retrieval was then conducted in a standard pressure cooker and slides were placed in 10mM 
citrate buffer (pH 6.0) for 20 minutes and allowed to cool. Slides were then blocked with 
normal Goat Serum (Biogenex, Fremont, CA) diluted in PBS with 1% bovine serum 
albumin (Santa Cruz Biotechnology, Dallas, TX) and 0.1% Tween 20 (Sigma, St. Louis, 
MO) for 1 hour.
Presence of tight junctions in the intestinal tissues was then assessed by incubating slides 
with a 1:100 dilution of Claudin-1 primary antibody (Novus Biologicals, NBP1-67515) 
overnight at 4 degrees Celsius. Following washing, Alexafluor 488 goat-anti-rabbit 
secondary antibody (Cell Signaling Technology, Danvers, MA) was applied and incubated 
for 2 hours at room temperature in a humidity chamber. Slides were then washed again and 
DAPI (Cell Signaling Technology) was applied at 1ug/ml and allowed to incubate at room 
temperature for 5 minutes. Slides were then rinsed in PBS, mounted, coverslipped, and 
assessed using a fluorescent microscope. Staining was repeated on additional slides to 
ensure reproducible results.
Tissue Cytokines
Intestinal, liver, and lung tissue segments (N=6-7/group) were thawed and homogenized in 
RIPA buffer (Sigma) with protease and phosphatase cocktail inhibitors (1:100 dilution, 
Sigma). Homogenates were centrifuged at 12,000 rpm to pellet extraneous tissue, and 
supernatants were transferred to fresh eppendorff tubes for storage at −80C. Total protein 
concentration was then quantified by Bradford Assay using a spectrophotometer (Versamax 
microplate reader, Molecular Devices). Tissue vascular endothelial growth factor (VEGF), 
granulocyte colony stimulating factor (GCSF), monokine induced by interferon gamma 
(MIG), Interleukin-6 (IL-6), and Interleukin-1 beta (IL-1β) were quantified with a Bioplex 
200 multiplex beaded assay system (Bio-Rad) using a customized multiplex kit for the 
designated chemokines (Millipore). Assays were performed at 1:25 dilution according to the 
manufacturer’s instructions.
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Statistical Analysis
Survival data were compared using the Mantel-Cox log-rank test and the Gehan-Breslow-
Wilcoxon test. Reperfusion data were deemed to be normally distributed based on histogram 
data inspection, and were compared with two way ANOVA and t test, when appropriate. 
Data are presented as percent change from baseline perfusion (mean% +/− SEM). Histology 
and multiplex cytokine data were not normally distributed, and as such, were compared 
using the Mann Whitney U test. Data are presented as the median with 25%-75% 
interquartile range. A P value of less than 0.05 was considered statistically significant.
RESULTS
hASCs Improved Survival Outcomes After Intestinal I/R Injury
Following intestinal I/R, seven day survival was 40% in the vehicle group and 20% in those 
treated with keratinocytes. Seven day survival significantly increased to 80% with the post-
ischemic application of hASCs (Figure 1, p<0.05). These data identify hASCs as providing 
significant survival advantages to mice after intestinal ischemia and reperfusion injury.
Post-Ischemic Mesenteric Perfusion Is Improved With The Use of hASC Therapy
Administration of hASCs following intestinal I/R improved post-ischemic mesenteric 
perfusion at both 12 and 24-hours of reperfusion compared to mice administered only 
vehicle (12 Hour Reperfusion: PBS Vehicle: 21.67+/−10.22% vs. hASC: 71.00+/−11.76%, 
p<0.05; 24 Hour Reperfusion: PBS Vehicle: 25.57+/−6.07% vs. hASC: 61.14+/−11.89%, 
p<0.05)(Figure 2). Improved mesenteric perfusion was also appreciated at 24-hours of 
reperfusion for the hASC group compared to the keratinocyte group (ASC: 61.14+/−11.89% 
vs. Keratinocyte: 25.00+/−11.38%, p<0.05), but this was not significant at 12-hours post 
ischemia. These results suggest that improved survival outcomes with hASC therapy 
following intestinal I/R may potentially be attributed to improved mesenteric perfusion 
following injury.
hASC Therapy Following Intestinal I/R Preserves Intestinal Tissue Architecture
Intestinal I/R resulted in significant sloughing of the intestinal mucosa at both 12 and 24 
hours following reperfusion in vehicle treated groups. This was seen as destruction of the 
epithelial layer in the crypt-villous architecture. Human ASC therapy following I/R abated 
this destruction and significantly decreased the median histology injury score (12 Hour 
Reperfusion: PBS Vehicle: 3.5 (25%-75%: 1.0-4.3) vs. hASC: 0 (25%-75%: 0.0-1.8), 
p<0.05; 24 Hour Reperfusion: PBS Vehicle: 4.0 (25%-75%: 2.0-5.0) vs. hASC: 0 
(25%-75%: 0.0-1.0), p<0.05) (Figure 3). Histology scores following keratinocyte therapy 
were similar to vehicle and were significantly worse than hASC groups. These results 
suggest that hASCs have a beneficial impact to the protection of intestinal mucosal integrity 
following I/R.
hASC Therapy Preserves Intestinal Tight Junction Architecture Following Injury
Animals exposed to hASCs following intestinal I/R injury demonstrated preservation of 
Claudin-1 tight junctional proteins in the expected boarder zones between intestinal 
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epithelial cells at 12 and 24 hours of reperfusion. Cell junctions stained brightly with 
Claudin-1 and the cell borders were crisply and clearly stained. Epithelial cells did not stain 
as strongly or as uniformly in PBS treated groups. Keratinocyte treated groups had 
decreased staining at 12 hours, and evidence of hazy boarders between cells at 24 hours, 
thereby suggesting disrupted gap junctions in these treated groups (Figure 4).
hASC therapy affects intestinal, hepatic, and pulmonary inflammatory tissue cytokine 
production
Intestinal tissue levels of GCSF were significantly decreased at 24 hours with the use of 
hASC therapy compared to PBS. Intestinal tissue levels of VEGF, MIG, IL-6, and IL-1β 
were not different between groups in intestinal tissues. Liver levels of GCSF were also 
significantly decreased in hASC groups at 24 hours of reperfusion compared to PBS or 
keratinocyte groups. Liver levels of IL-1β were significantly lower in hASC groups 
compared to keratinocytes at 12 hours of reperfusion, but no difference was seen at 24 hours 
(Table 1).
hASC therapy seemed to have the most significant impact on pulmonary inflammation 
following intestinal ischemia and reperfusion injury. Levels of GCSF, MIG, IL-6, and IL-1β 
were all significantly decreased in hASC groups at 24 hours of reperfusion compared to PBS 
or keratinocyte groups. Levels of pulmonary VEGF were also significantly elevated in hASC 
groups at 24 hours of therapy compared to PBS control, but were not significantly different 
from keratinocyte groups (Table 1).
DISCUSSION
Intestinal ischemia originates from multiple etiologies and can affect diverse patient 
demographics. No definitive medical advancements have been made in the treatment of 
intestinal ischemia in the last decade and therefore the development of novel treatment 
modalities is paramount. The ultimate therapeutic goal in patients with intestinal ischemia is 
to restore blood flow to ischemic tissues prior to the development of necrosis and bowel wall 
perforation. In this study, we observed that hASCs significantly increased survival and 
mesenteric perfusion while simultaneously preserving intestinal histological and tight 
junction architecture compared to keratinocytes or vehicle in a murine model of intestinal 
ischemia and reperfusion injury. In addition, hASCs abated the systemic inflammatory 
response, as seen predominantly by a decrease in lung tissue inflammatory markers.
While previous studies have demonstrated the therapeutic benefits of hASCs in attenuation 
of other animal models of I/R injury [21], this is the first study to demonstrate the efficacy of 
human ASCs in rescuing murine intestinal ischemia. Previous studies have suggested that 
ASCs provide their benefit at least in part, by the release of paracrine factors [22, 23]. There 
are likely multiple growth factors and immune modulators that play a role in end organ 
protection, and current studies by our group are attempting to define which of these factors 
may be the most efficacious in acute organ protection following injury.
Decreased mortality with hASC therapy was likely related to improved mesenteric perfusion 
and mucosal integrity. Improved perfusion likely restored blood flow and tissue oxygen 
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levels to physiologic levels, which then prevented intestinal mucosal injury, sloughing, and 
the impending bacterial translocation and sepsis that would have ensued due to cell junction 
degradation. This concept was seen in this study by preservation of histological architecture 
and the tight junction protein claudin-1 in those animals treated with hASCs. It is unclear 
though, how the hASCs promoted improved mesenteric perfusion, but it may be in part to 
the release of specific vasodilators such as nitric oxide or hydrogen sulfide [24, 25] from 
these cells. Future studies aim to determine the specific properties of the hASCs that 
promote improved vascular perfusion and survival.
GCSF and MIG are two chemokines that are associated with inflammation and leukocyte 
infiltration, while IL-1β and IL-6 are notable proinflammatory cytokines associated with the 
acute phase response [26-29]. hASC treated groups exhibited a reduced systemic 
inflammatory response as noted by a decrease in these pulmonary inflammatory markers 
assessed at 24 hours of reperfusion. It is unclear though as to why levels of these markers 
were not significantly altered in intestinal and hepatic tissues over the same time periods. 
Preservation of tight junctions and intestinal integrity with hASC therapy may have 
ameliorated the systemic inflammatory response and likely contributed to improvements in 
animal survival.
Clinical Considerations to Stromal Cell Therapy
The clinical use of hASCs in patients with intestinal ischemia provides a novel treatment 
option for a disease process that has not had a sound medical advancement in many years. 
Initial ASC clinical trials in other organ systems have been quite promising. 
Transendocardial injection of ASCs in patients with no-option ischemic cardiomyopathy 
indicated that autologous transplantation of ASCs was not only safe, but also preserved 
ventricular function, myocardial perfusion, and functional capacity [30]. Another study 
using autologous ASCs in patients with non-revascularizable critical limb ischemia 
demonstrated that ASCs improved wound healing, decreased pain, and expedited recovery 
time [31]. Trials in patients with Crohn’s disease and complex perianal fistulas showed 
reduced fistula size and improved recovery when patients were administered ASCs [32].
Multiple animal studies and now several clinical trials have demonstrated extremely 
promising results with the use of ASC therapy. Challenges that face initiating clinical trials 
in human subjects with intestinal ischemia include identifying the most appropriate patients 
for whom to offer therapy. Many previous initial clinical trials have utilized patients in 
whom surgical revascularization was not an option. In the case of intestinal ischemia, 
patients who undergo surgical resection of necrotic bowel, but who have marginally 
ischemic boarder zones of intestine may be the best candidates for initial therapeutic trials. 
With the aid of second look laparotomy, surgeons could apply the cells on the day of 
intestinal resection, temporarily close the abdomen, and return to the operating room in 
24-48 hours to assess the viability of the remaining intestines.
An additional challenge to therapy is identifying the optimal stromal cell source (bone 
marrow, adipose tissue, umbilical cord), as well as determining the donor type for therapy 
(allogenic versus autologous). Risks to allogenic therapy include potential immunogenic 
reactions to foreign cells, although this is less likely given the ability of mesenchymal 
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stromal cells to down-regulate T-cell proliferation [33]. Finally, risks of malignancy are 
always considered with stromal cell therapy given the highly proliferative potential of these 
cells. The risks of malignancy in the future would need to be balanced with the risks of 
mortality and morbidity at the time of therapeutic use.
Limitations to this study
This study has several limitations that may affect the impact of the results. The first 
limitation is that human cells were utilized as a preclinical assessment in a mouse model of 
intestinal ischemia and reperfusion injury. While xenotransplantation may be less desirable, 
the use of stromal cells from animals is certainly feasible. Mesenchymal stromal cells have 
unique immunomodulatory properties that suppress T-lymphocyte proliferation and allow 
them to be used in different [33]. There have been over 25 different studies where human 
mesenchymal stromal cells have been placed into immunocompetent hosts of different 
species [3, 34]. Interestingly, in the majority of these cases, the cells survived several weeks 
and engrafted into the host tissue [35].
A subsequent limitation to the study is that the SMA ligation model of intestinal I/R does 
not model clinical intestinal ischemia to its fullest. Although complete small bowel ischemia 
is possible secondary to SMA thrombus or embolus, the majority of intestinal ischemic 
episodes are due to segmental intestinal ischemia, such as may be seen with adhesive bowel 
obstructions or incarcerated hernias. Nonetheless, the SMA ligation model mimics the most 
severe form of intestinal ischemia, and therefore, is likely the best animal model available to 
test the effectiveness of new therapies.
Additionally, a limitation exists in the assessment of tissue cytokines. Despite normalizing 
for total protein concentration, a wide variation of levels was observed between group 
samples. Although the same relative area of intestine, liver, and lung was procured from 
each subject, it is likely that tissue levels of cytokines are not exactly equal throughout even 
small segments of tissue.
CONCLUSION
Adipose-derived stromal cells have shown promise as a potential novel treatment option for 
patients with intestinal ischemia. More specifically, we observed that human ASCs improve 
survival outcomes, improve mesenteric perfusion and intestinal histologic architecture, and 
decrease systemic inflammation. Clinical trials that utilize hASCs for the treatment of 
intestinal ischemia are certainly on the horizon, but a clear understanding of the mechanism 
of action must be addressed to ensure the safety and efficacy of therapy prior to widespread 
clinical use.
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Figure 1. hASC therapy improves survival following intestinal ischemia
The use of hASCs increased seven day survival to 80% compared to a 40% seven day 
survival in vehicle control following intestinal ischemia. No survival benefit was seen with 
the use of keratinocytes (differentiated cell control). I/R = ischemia and reperfusion; hASC = 
Human adipose-derived stromal cell
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Figure 2. hASCs increase mesenteric perfusion following ischemia
The use of human adipose stromal cells significantly increased mesenteric perfusion above 
vehicle at both 12 and 24 hours following injury. hASCs also were found to promote better 
mesenteric perfusion compared to keratinocytes (differentiated cellular control) at 24 hours 
following injury. hASC = Human adipose-derived stromal cell
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Figure 3. hASCs improve intestinal histology following ischemic injury
Infusion of PBS vehicle (A, D) and keratinocytes (C,F) were associated with sloughing of 
the mucosa and transmural necrosis. hASC therapy (B,E) following intestinal injury 
inhibited this damage. Intestinal segments were scored according to Watkins, et al [36] and 
hASC therapy had significantly lower histology scores at both 12 and 24 hours of 
reperfusion. hASC = Human adipose-derived stromal cell
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Figure 4. Human adipose derived stromal cell therapy during intestinal ischemia preserves 
claudin-1 tight junction proteins
Infusion of PBS vehicle (A,D) and keratinocytes (C,F) were associated with less 
immunofluorescence staining of Claudin-1 in intestinal tissue segments. Infusion of hASCs 
(B,E) preserved claudin-1 integrity following 12 and 24 hours of reperfusion as noted by 
more uniform, robust, and crisp staining of claudin-1 at the epithelial cell boarders. hASC = 
Human adipose-derived stromal cell
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Table 1
Assayed Chemokines in Intestinal, Hepatic, and Pulmonary Tissues Following Cellular Therapy for Intestinal 
I/R
12 hour Reperfusion 24 hour Reperfusion
PBS hASC Keratinocytes PBS hASC Keratinocytes
Intestine VEGF 49.31 48.5 40.1 47.5 52.7 52.1
34.2-65.8 20.6-66.3 0-49.6 29.2-71.2 27.8-80.8 0-106.6
GCSF 291.9 300.8 396.7 1609 201.4 * 487.2
32.3-958.3 77.4-1477 97.3-1700 1379-3533 178.7-410.2 210.3-2557
MIG 523.4 316.9 453.8 399.8 534.5 604.4
314.6-707.5 245.2-389 373.5-487.8 345.6 568.1 396.0-738.0
IL6 961.1 210.5 716.7 235.7 91.56 164.9
52.3-2860 122.6-1004 70.0-1413 136.5-582.2 51.03-144.8 81.2-1169
IL1β 49.3 48.5 40.4 47.5 52.7 52.1
34.2-65.8 20.6-66.3 0-49.6 29.2-71.2 27.8-80.8 0-106.6
Liver VEGF 22.8 21 19.5 27.7 36.1 22.1
19.4-27.6 18.0-30.0 15-24.5 17.6-39.3 19.7-42.8 12.1-27.8
GCSF 17.1 42.1 239 197 25.2 *# 157.8
11.8-158.5 8.2-216.3 29.0-296.0 112.2-343.1 23.4-46.1 79.6-370.1
MIG 183.7 133.1 571.8 142 163.5 351.8
108.2-281.6 113.7-228.9 326.6-654.7 118.0-205.6 93.2-183.8 106.0-396.7
IL6 85.2 92.1 121.4 122.2 76.1 111.5
67.1-195.6 78.2-155.5 113.6-137.7 69.1-131.5 69.6-95.6 71.2-166.1
IL1β 30.6 42.8 *# 21.7 43.2 46.2 30
23.0-33.1 30.8-56.5 18.1-31.6 26.7-64.2 20.6-60.5 21.1-30.1
Lung VEGF 77.8 70.1 49.4 23 128.1 * 75.1
46.5-91.5 35.1-75.3 28.0-83.8 20.7-73.1 81.0-145.7 37.8-83.5
GCSF 104.3 94.1 785.2 958 83.1 *# 542.5
43.3-1639 34.2-906.9 518.1-1339 512.7-1782 50.1-167.8 430.8-2154
MIG 66.5 69.7 # 266.7 89.7 59.9 # 128.6
59.7-83.4 40.2-124.3 149.4-277.6 63.8-132.7 49.3-82.0 97.1-138.1
IL6 69.3 26.5 361.3 68.8 0 *# 153.6
14.5-3661.0 14.02-210.7 78.1-1105 18.4-103.7 0-11.6 84.2-1382.0
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12 hour Reperfusion 24 hour Reperfusion
PBS hASC Keratinocytes PBS hASC Keratinocytes
IL1β 56.8 36.9 59.2 40.6 33.1 *# 52.6
38.6-100.9 22.6-71.1 54.3-63.2 33.7-58.6 29.6-56.2 39.9-67.8
*p<0.05 versus PBS
#p<0.05 versus keratinocytes
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